Efficacy of Radiotherapy Combined with EGFR-TKI in the Treatment of EGFR/TP53 Co-Mutated NSCLC

被引：0
|
作者：
Zeng, S. [1 ]
Wang, L. L. [1 ]
Tao, D. [1 ]
Zhou, W. [1 ]
Wu, Y. [2 ]
机构：
[1] Chongqing Univ Canc Hosp, Dept Radiat Oncol, Chongqing, Peoples R China
[2] Chongqing Univ, Coll Med, Chongqing, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 120卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2189
引用
收藏
页码：E86 / E86
页数：1
相关论文
共 50 条
  • [31] ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
    Zhijie Wang
    Zhenxiang Li
    Xiaosheng Ding
    Zhirong Shen
    Zhentao Liu
    Tongtong An
    Jianchun Duan
    Jia Zhong
    Meina Wu
    Jun Zhao
    Minglei Zhuo
    Yuyan Wang
    Shuhang Wang
    Yu Sun
    Hua Bai
    Jie Wang
    Scientific Reports, 5
  • [32] Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
    Kunimasa, Kei
    Nishino, Kazumi
    Sato, Yoshiharu
    Mori, Masahide
    Ihara, Shoichi
    Suzuki, Hidekazu
    Nagatomo, Izumi
    Kumagai, Toru
    Morishima, Toshitaka
    Imamura, Fumio
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [33] A Meta-Analysis and Bioinformatics Exploration of the Prognostic Value of TP53 Co-Mutations in EGFR Mutated NSCLC
    Jiang, R.
    Wang, F.
    Li, S.
    Wang, X.
    Wang, L.
    Huang, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S670 - S670
  • [34] Cytoplasmic ERβ expression to predict efficacy and survival of EGFR-TKI in EGFR-mutant NSCLC
    Wang, Zhijie
    Wang, Jie
    Wang, Xiaodong
    Shen, Zhirong
    Ding, Xiaosheng
    Bai, Hua
    Duan, Jianchun
    An, Tongtong
    Wang, Yuyan
    Zhuo, Minglei
    Wang, Shuhang
    Wu, Meina
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] Efficacy and Toxicity of EGFR-TKI in Frail NSCLC with EGFR Mutation: A Retrospective Analysis in a Single Institution
    Akazawa, Y.
    Yoshikawa, A.
    Hashimoto, K.
    Kanazu, M.
    Yano, Y.
    Yamaguchi, T.
    Mori, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1002 - S1002
  • [36] Re-administration of EGFR-TKI to mutated EGFR NSCLC patients after remission of osimertinib induced ILD
    Chikamori, Kenichi
    Maeda, Tadashi
    Sakamoto, Kenji
    Aoe, Keisuke
    Utsunomiya, Toshiaki
    Murata, Yoriyuki
    Nakanishi, Masamoto
    Kamei, Haruhito
    ANNALS OF ONCOLOGY, 2019, 30
  • [37] Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC
    Urbanska, Edyta M.
    Grauslund, Morten
    Koffeldt, Peter R.
    Truelsen, Sarah L. B.
    Loefgren, Johan O.
    Costa, Junia C.
    Melchior, Linea C.
    Sorensen, Jens B.
    Santoni-Rugiu, Eric
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (17)
  • [38] Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib
    Chih-Hsi Scott Kuo
    Chi-Hsien Huang
    Chien-Ying Liu
    Stelios Pavlidis
    Ho-Wen Ko
    Fu-Tsai Chung
    Tin-Yu Lin
    Chih-Liang Wang
    Yi-Ke Guo
    Cheng-Ta Yang
    Targeted Oncology, 2019, 14 : 433 - 440
  • [39] Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib
    Kuo, Chih-Hsi Scott
    Huang, Chi-Hsien
    Liu, Chien-Ying
    Pavlidis, Stelios
    Ko, Ho-Wen
    Chung, Fu-Tsai
    Lin, Tin-Yu
    Wang, Chih-Liang
    Guo, Yi-Ke
    Yang, Cheng-Ta
    TARGETED ONCOLOGY, 2019, 14 (04) : 433 - 440
  • [40] ONO-7475, a novel AXL inhibitor, suppresses the adaptive resistance to initial EGFR-TKI treatment in EGFR-mutated NSCLC
    Okura, Naoko
    Taniguchi, Hirokazu
    Tanimura, Keiko
    Horinaka, Mano
    Sakai, Toshiyuki
    Tanaka, Kohei
    Kozaki, Ryohei
    Yano, Seiji
    Yamada, Tadaaki
    CANCER SCIENCE, 2021, 112 : 891 - 891
12345